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BACKGROUND: The validity of circulating tumour DNA (ctDNA) as an indicator of disease progression compared to medical
imaging in patients with metastatic melanoma requires detailed evaluation.
METHODS: Here, we carried out a retrospective ctDNA analysis of 108 plasma samples collected at the time of disease progression.
We also analysed a validation cohort of 66 metastatic melanoma patients monitored prospectively after response to systemic
therapy.
RESULTS: ctDNA was detected in 62% of patients at the time of disease progression. For 67 patients that responded to treatment, the
mean ctDNA level at progressive disease was signiﬁcantly higher than at the time of response (P < 0.0001). However, only 30 of these 67
(45%) patients had a statistically signiﬁcant increase in ctDNA by Poisson test. A validation cohort of 66 metastatic melanoma patients
monitored prospectively indicated a 56% detection rate of ctDNA at progression, with only two cases showing increased ctDNA prior to
radiological progression. Finally, a correlation between ctDNA levels and metabolic tumour burden was only observed in treatment
naïve patients but not at the time of progression in a subgroup of patients failing BRAF inhibition (N = 15).
CONCLUSIONS: These results highlight the low efﬁcacy of ctDNA to detect disease progression in melanoma when compared mainly
to standard positron emission tomography imaging.
British Journal of Cancer (2022) 126:401–408; https://doi.org/10.1038/s41416-021-01507-6

INTRODUCTION
Metastatic melanoma is the most aggressive type of skin cancer and
is responsible for most skin cancer-related deaths [1, 2]. In the past
decade, the clinical management of patients with advanced
melanoma was revolutionised by the use of anti-programmed cell
death 1 (PD1) and/or anti-cytotoxic-T-lymphocyte-associated antigen 4 (CTLA-4) immunotherapies, as well as BRAF/MEK inhibiting
targeted therapies [3]. These treatments have signiﬁcantly increased
the 5-year survival rate of melanoma patients, which is currently at
52% for the nivolumab plus ipilimumab, 44% for nivolumab alone,
26% for ipilimumab and 34% for dabrafenib/trametinib [4, 5].
Imaging scans, such as 18F-labelled ﬂuorodeoxyglucose positron
emission tomography (FDG-PET) or computerised tomography (CT),
are currently the clinical standard for treatment monitoring, but are
costly and of limited accessibility in rural areas. Nonetheless, disease
progression occurs in a large proportion of patients, even after
treatment cessation [6]. Thus, biomarkers that can aid clinicians in
accurately detecting progressive disease in patients are critical.
1

Circulating tumour DNA (ctDNA) is progressively used as a marker
of disease status in multiple types of cancers, including melanoma [7].
This non-invasive real-time biomarker has been demonstrated to
accurately reﬂect pretreatment tumour burden [8, 9], provide
predictive or prognostic information and is a useful monitoring tool
for treatment response [10–12]. However, very few studies [13–16]
have deﬁned the clinical validity of ctDNA to effectively identify
disease progression in a large cohort of melanoma patients compared
to medical imaging, the current gold standard for disease monitoring.
In this study, we quantiﬁed plasma ctDNA (N = 108) at the time
of radiological disease progression in a cohort of metastatic
melanoma patients treated with systemic therapy in the context
of real-world clinical practice. We further evaluated the potential
of ctDNA to detect disease progression in a prospective cohort of
patients (N = 66). Finally, we evaluated the correlation between
ctDNA levels and metabolic tumour burden (MTB) prior to
treatment and at the time progression in a subgroup of patients
treated with BRAF/MEK inhibitors (N = 15).
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MATERIALS AND METHODS
Patients
Metastatic melanoma patients undergoing systemic therapies were
enrolled in the study between 2013 and 2019 at Sir Charles Gairdner
Hospital (SCGH) and Fiona Stanley Hospital (FSH) in Perth, Western
Australia. Written informed consent was obtained from all patients under
approved Human Research Ethics Committee protocols from Edith Cowan
University (Nos. 11543 and 18957) and SCGH (Nos. 2007-123 and 2013-246)
in compliance with the Declaration of Helsinki. Experiments were
performed according to institutional and national guidelines and
regulations.
We retrospectively selected patients who had plasma samples collected
close to the time of the ﬁrst unequivocal radiological scan indicating
disease progression (PD) after commencing therapy, i.e. either 1 week
before or up to 4 weeks of PD, but without any change in treatment. Blood
samples were collected in EDTA vacutainer or in Cell-Free DNA BCT®
(Streck, La Vista, NE). Within 24 h of blood collection, plasma was separated
by centrifugation at 300 × g for 20 min, followed by second centrifugation
at 4700 × g for 10 min. Isolated plasma was stored at −80 °C until
extractions were performed. A total of 108 plasma samples from 93
patients were included in this analysis. For 15 patients, samples collected
at progression to ﬁrst- and second-line treatment were included in the
analysis. Plasma samples at the time of best overall clinical response to
therapy were available for 62 of the 108 cases investigated and were
compared with ctDNA levels at progressive disease.
For the prospective analysis, a total of 66 patients were enrolled and
monitored for plasma ctDNA every 3–12 weeks, with a median follow-up
duration of 66 weeks (range 26–110 weeks). All blood samples were
collected in Cell-Free DNA BCT® (Streck) and plasma was stored at −80 °C
until extractions were performed.

ctDNA assessment
Selection of mutational targets for ctDNA analysis was identiﬁed via
standard pathology protocols or using a customised melanoma nextgeneration sequencing (NGS) panel (Illumina, San Diego, CA, USA) as
described by Calapre et al. [17], based on the following criteria: (i) known
melanoma hotspot mutation inBRAF, NRAS and/or TERT promoter; (ii)
COSMIC/TCGA reported melanoma-associated mutations; (iii) other mutation with a PolyPhen score > 0.7 and high variant allele frequency in the
tumour. Commercially available and/or customised probes were used to
analyse ctDNA by droplet digital PCR (ddPCR). A list of all mutations used
for ctDNA detection is provided in Table S1. The limit of blank for each
assay used for ctDNA detection was previously reported by Calapre et al.
[17] and Marsavela et al. [18].
Cell-free DNA (cfDNA) was extracted from plasma using the QIAamp
Circulating Nucleic Acid Kit (Qiagen, Hilden, Germany). Extracted cfDNA
was then analysed by ddPCR as previously described [12]; samples that
were negative in the ﬁrst instance were tested further in duplicate to
complete a triplicate set. A positive control, a healthy control and a notemplate control were included in each run. Only tests providing >10,000
droplets were used for analysis.

Disease progression assessment
Tumour disease progression was assessed radiologically by CT and/or FDGPET scans. Magnetic resonance imaging (MRI) of the brain was also used
where indicated. Patients were considered to have PD if they developed
new lesions, had a signiﬁcant increase in tumour size as per RECIST 1.1 or
iRECIST on CT, had increased metabolic activity on FDG-PET scan or
presented a new or enlarging clinical lesion, conﬁrmed by the treating
clinician. Clinicians were blinded to the ctDNA result at the time of
the scan.

MTB analysis
MTB was calculated from FDG-PET scans as described previously [8, 17]. All
images were reviewed retrospectively by an experienced nuclear medicine
physician (ZA-O) blinded to the ctDNA analysis. Total lesion glycolysis,
which combines volumetric and metabolic information, was calculated for
MTB evaluation [19, 20]. Analyses were conducted on a Siemens Syngo via
workstation (Siemens Healthcare GMbH, Erlangen, Germany).

Statistics

Differences between ctDNA levels were estimated by unpaired t test from
the log-transformed data. Differences between the detection rates were

assessed using two-sided Fisher’s exact test. Paired t test was used to
evaluate the difference between ctDNA levels at the time of response and
clinical progression. All variables were tested for normality and equality
variance. Statistical differences between ctDNA levels at the time of
response and progression in the same individual were also assessed using
a Poisson distribution test, using calculated mutant DNA concentrations
and the number of DNA occupied droplet counts as analytical variables
[21]. Correlations between MTB and ctDNA were carried using Pearson’s
correlation of the log-transformed values. Statistical analyses were
performed using R version 5.2, GraphPad Prism version 5 and SPSSv22.0.
Results were considered statistically signiﬁcant at P < 0.05.

RESULTS
ctDNA detection at disease progression
We retrospectively selected 108 plasma samples collected at the
time of disease progression to determine the rate of ctDNA
detection. Patient characteristics and clinical parameters for both
cohorts are summarised in Table 1. The overall detection rate was
62% and was independent of the tumour BRAF mutational status
(Fig. 1a). When subdivided by disease stage, patients with visceral
metastases at progression (M1c and M1d with extracranial
metastases) had higher ctDNA levels and detection rates
compared to those patients who progressed with lymph node,
subcutaneous or lung lesions (Fig. 1b). Only 9 of 19 cases with
metastases in the skin, subcutaneous tissue or lymph node (M1a,
47%) had detectable ctDNA at progression. In addition, only two
of the ﬁve cases with lung metastases (M1b, 40%) had detectable
ctDNA. Notably, all but one of the nine patients with the
intracranial disease only (M1d IC only) had undetectable ctDNA
at the time of progression, in contrast to the high detection rate
amongst those with extracranial involvement.
From a total of 108 cases, 67 (62%) showed a response to
therapy prior to progressive disease. Interestingly, patients who
responded to treatment had signiﬁcantly lower ctDNA levels at
disease progression (P = 0.046; Fig. 2a). Moreover, the detection
rate was signiﬁcantly lower in patients who responded (35/67,
52%) compared to those who did not respond to therapy and had
no tumour size reduction (32/41, 78%, P = 0.008).
In this subgroup of patients with samples taken at the time of
response to treatment and PD, paired comparison of ctDNA levels
showed a signiﬁcant increase in ctDNA at progression relative to
the point of response or nadir (N = 67, P < 0.0001; Fig. 2b). Of
these, 22 cases (34%) had undetectable ctDNA at the time of best
response, which became positive at progression. However, only
30/67 (45%) of all cases had a signiﬁcant increase in ctDNA level
when ddPCR results are compared using a Poisson test.
ctDNA detection at the time of progression in a prospective
cohort
To validate these results, we prospectively recruited a total of 66
metastatic melanoma patients either commencing or undergoing
systemic treatment, including two cases treated with adjuvant
therapy after removal of isolated tumour metastases. Of the 64
patients with active disease, 14 did not respond to therapy and
were excluded from the analysis. Of the 52 patients with objective
responses (N = 50) or who had adjuvant therapy (N = 2), 23 (44%)
experienced progression during the follow-up period. However,
for seven cases, we did not have a blood collection for ctDNA
analysis within 2 weeks of disease progression. Therefore, followup collections for a total of 45 patients, 16 with PD and 29 with the
ongoing response, were included in the ﬁnal analysis presented in
Fig. 3. The clinical characteristics of these 45 patients can be found
in Table 1. The majority of patients were males (101/153, 66%) and
treated with combination therapy, either dabrafenib/trametinib
(70/153, 46%) or ipilimumab/nivolumab (30/153, 20%). The
prospective cohort largely consisted of patients who received
immunotherapy and the proportion of BRAF mutants was lower
than in the retrospective cohort.
British Journal of Cancer (2022) 126:401 – 408
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Table 1.

Clinical characteristics at baseline of the melanoma samples
included in the study.

Variable

Retrospective
cohort, N = 108 (%)

Prospective
cohort, N = 45 (%)

≤60

54 (50)

24 (53)

>60

54 (50)

21 (47)

Female

38 (35)

14 (31)

Male

70 (65)

31 (69)

BRAF mutant

81 (75)

32 (71)

NRAS mutant

11 (10)

4 (9)

BRAF/NRAS WT

16 (15)

9 (20)

Pembrolizumab

22 (20)

6 (13)

Ipilimumab/Nivolumab

15 (14)

15 (34)

Ipilimumab

11 (10)

Age

Gender

Mutation status

Treatment
ICI

Targeted therapies
Vemurafenib

3 (3)

Dabrafenib/Trametinib

54 (50)

16 (36)

2 (2)

4 (9)

1 (1)

1 (2)

Vemurafenib/
Cobimetinib

1 (2)

Adjuvant
Nivolumab
Clinical trials

2 (4)

No progressive disease

–

29 (64)

Progressive disease

108 (100)

16 (36)

Response prior to PD
Yes

67 (62)

16 (36)

ctDNA not
elevated at PD

34 (31)

7 (16)

ctDNA
elevated at PD

33 (31)

9 (20)

ctDNA statistically
elevated at PD

20 (19)

5 (11)

No

41 (38)

–
N = 16

AJCC stage/M
classiﬁcation at PD
M1a

19 (18)

5 (31)

M1b

5 (5)

2 (13)

M1c

51 (47)

4 (25)

M1d

33(30)

5 (31)

Yes

9 (8)

4 (25)

No

99 (92)

12 (75)

Brain-only metastasis at PD

ICI immune checkpoint inhibitors, PD progressive disease.

Most patients experiencing disease progression were treated
with BRAF/MEK inhibitors (11/16, 69%, Fig. 3). Amongst the 16
patients who relapsed, disease progression was detected at a
median time of 31 weeks from the commencement of treatment
(range 10–64 weeks). Only 9 of 16 patients had elevated ctDNA
levels at the time of progression (56%; Fig. 3). From the nine
patients with increased ctDNA levels at disease progression,
except for case #1069, all others had a signiﬁcant increase in
ctDNA level when ddPCR results were compared using Poisson
statistics. By contrast, seven cases remained ctDNA negative
despite radiological disease progression (44%). Of these, three had
British Journal of Cancer (2022) 126:401 – 408

intracranial disease-only progression (red asterisks; Fig. 3). Of note,
one of the three patients with the intracranial disease only (#1069)
developed a leptomeningeal disease and had a detectable but
low plasma ctDNA (1.4 copies/mL) at progression.
Notably, four patients had no detectable plasma ctDNA at the
time of progression with clear extracranial disease. One patient
showed progression in the right external iliac node (#693), one
had a new subcutaneous lesion on the left thigh (#1093), another
developed several new bilateral pulmonary nodules at the time of
progression (#806) and one (#1108) showed bone recurrence at
the T2 vertebral body.
For two cases ctDNA became detectable 10–25 weeks prior to
radiological disease progression (Fig. 3). Patient #974 showed
partial response prior to progressive disease in lung and lymph
nodes detected by PET scans. Analysis of plasma collected
24 weeks prior to progression indicated an increase in ctDNA
levels, but radiological examination demonstrated no evidence of
progressive disease. Similarly, patient #825 showed increasing
ctDNA levels at ~13 weeks before the clinical and radiological
progressive disease was identiﬁed in multiple lymph nodes,
gallbladder, duodenum and subcutaneous nodules.
Patients without unequivocal disease progression (N = 29) were
also followed up for a median of 66 weeks (range 26–110). Plasma
ctDNA was undetectable in the majority of plasma samples.
However, we observed that ten patients (34%) had intermittent
low ctDNA levels without apparent clinical cause. Of note, ctDNA
levels were always below 10 copies/mL and undetectable in later
follow-up samples.
Correlation between ctDNA levels versus MTB at baseline and
disease progression
Previously, we observed that in pretreatment samples from
metastatic melanoma patients, ctDNA plasma concentrations
strongly correlated with MTB derived from PET scans [8]. Here,
we investigated the correlation between ctDNA and MTB at the
time of progression in 15 patients treated with dabrafenib plus
trametinib with matching samples at baseline and progression.
We selected this subgroup as they constitute the majority of
patients monitored in this study who developed disease progression after an objective response during the ctDNA monitoring
period.
While we found a strong correlation between ctDNA and MTB at
baseline (r = 0.8659, P < 0.0001), no correlation was apparent at
disease progression (r = 0.4923, P > 0.05) (Fig. 4). These results
suggest that ctDNA levels do not reﬂect disease burden and its
metabolic activity at progression.
DISCUSSION
The high number of therapies available for late-stage melanoma
necessitates an efﬁcient stratiﬁcation of patients to appropriate
treatments. In addition, rigorous monitoring for timely detection
of disease progression is also necessary, to ensure swift
modiﬁcation of treatment and improve patient outcomes. Plasma
ctDNA has been heralded as an alternative pathway to monitor
disease in cancer patients, and can potentially provide lead time
to overt progression within which treatment could be modiﬁed
[13]. Here, we made use of a real-world cohort of metastatic
melanoma patients to determine the reliability of ctDNA for the
detection of disease progression. Our results demonstrated that
ctDNA elevation was only able to indicate the progression in
52–56% of patients, highlighting the limitations of ctDNA as a
reliable marker to monitor progression alone.
We observe that low ctDNA copies (<10 copies/mL of plasma)
were detected sporadically in patients who do not show
radiological progression. Therefore, stringent criteria are
required to indicate disease progression by ctDNA detection.
We attempted to address this by conducting a Poisson test to
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Fig. 1 ctDNA quantiﬁcation in melanoma patients at the time of progressive disease on systemic therapy. a Plasma ctDNA levels (copies/
mL of plasma) in melanoma samples (N = 108), stratiﬁed by mutation status. Red dots identify patients with the intracranial disease only. b
M1d cases were further subdivided into those with extracranial (IC + EC) and those with brain-only metastases (IC only). Percentages denote
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Fig. 2 Plasma ctDNA levels are relative to progression. a Plasma ctDNA levels (copies/mL of plasma) in melanoma samples at the time of
progression in patients who had a response to therapy (R) or did not show response to treatment (NR). The geometric mean of ctDNA
concentrations is indicated for each group by a line. The P values of a t test comparing the log-transformed ctDNA levels and Fisher’s exact test
comparing detection rates are indicated above each comparison. b Changes in ctDNA levels between the time of response and the time of
progression. Percentages denote the frequency of patients with detectable ctDNA. Red dots identify patients with intracranial disease only.
The geometric mean of ctDNA concentrations is indicated for each group by a line. Paired t test P value of the log-transformed ctDNA levels is
indicated above the graph.

determine statistically signiﬁcant increases in ctDNA. Accordingly, only 30 of 67 (45%, retrospective cohort) and 8 of 9 (89%,
prospective cohort) patients were found to have a statistically
signiﬁcant increase in ctDNA concentration at PD relative
to the response. Overall, this reduces the rate of ctDNA
detection to 47%. These results highlight the low efﬁcacy of
ctDNA to detect PD in most patients when compared to
standard PET imaging.
Notably, one major challenge for the use of ctDNA as a
monitoring biomarker of progressive disease is the lack of
detectable tumour-derived fragments in the plasma of patients
with brain metastases [22, 23]. In our study, 3 of the 7 (43%)
ctDNA-negative patients in the prospective study and 8 out of 41
(20%) of ctDNA-negative cases in the retrospective study had
intracranial disease only at the time of progression. Accounting for
patients who had an initial response to therapy in both the

retrospective and prospective cohort, a signiﬁcant proportion had
intracranial disease progression (12–19%). The presence of
isolated brain metastases poses a signiﬁcant limitation for the
use of plasma ctDNA as a surveillance biomarker, considering that
at the time of diagnosis of metastatic melanoma nearly 20% of
patients will only have metastasis in the brain and >50% of
patients undergoing targeted therapies or immunotherapies will
eventually develop the progressive disease in the brain [24–26].
Thus, for these patients, plasma ctDNA is not suitable for
monitoring disease progression, and MRI may remain a critical
modality for monitoring disease progression in melanoma. Nonetheless, previous research [27–30] has shown that ctDNA is
detectable in the cerebrospinal ﬂuid (CSF) of cancer patients with
brain metastases only. Assessment of the dynamic changes of
ctDNA in CSF, but not in plasma, is potentially a valid surrogate
marker in such situations.
British Journal of Cancer (2022) 126:401 – 408
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Immunotherapy with anti-CTLA-4 or anti-PD-1 agents presents a challenge for oncologists due to pseudoprogression. This
pattern is deﬁned as initial radiographic tumour growth
followed by regression and occurs in 10–15% of patients with
metastatic disease [31, 32]. This delayed immune response could
lead to an erroneous indication of refractory disease, which is
associated with ctDNA negativity [33]. In this study, disease

British Journal of Cancer (2022) 126:401 – 408

progression by radiological scans were all conﬁrmed by a
second scan that shows disease progression or a tumour biopsy
that conﬁrms malignancy. Based on these parameters, the lack
of ctDNA at progression was therefore not attributable to
potential pseudoprogression events.
Despite the strong suggestions that ctDNA may provide a lead
time for detection of disease progression [9, 12–14], here we
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observed that ctDNA failed to successfully detect disease
progression in patients that initially responded to therapy. Only
a few studies have previously assessed the ctDNA detection rate at
disease progression in melanoma. Rowe et al. [14] presented a
detection rate of 100% in a small cohort of ﬁve patients that
developed disease progression after showing response to therapy.
Moreover, they reported detectable ctDNA in four of these
patients prior to radiological detection of progression. However,
the statistical signiﬁcance of this increase is not described.
Similarly, Haselmann et al. [13] has also reported a high
percentage of cases with ctDNA detection prior to radiological
progression (61%, N = 11/18). However, the prior response to
therapy in these patients is unclear. In addition, from the 18 cases
monitored, 14 cases had detectable ctDNA at disease progression
(78%). More recently, Váraljai et al. described that ctDNA increase
preceded radiologic progression with an average lead time
window of 3.5 months in 86% of the 36 melanoma patients
[34]. A study by Schreuer et al. described an increase in BRAF
mutant ctDNA in patients treated with targeted therapies at the
time of radiological disease progression assessed by PET scans in
36 patients. This increase was detected with a sensitivity of 70%
(N = 19/27) and speciﬁcity of 100% [16]. Based on our results and
that of others, there is currently no congruence of ctDNA
detection rate at PD in melanoma, and therefore further studies
are required to elucidate factors inﬂuencing these results.
The lower detection rate reported in our study, in contrast to
the above-mentioned reports, may be inﬂuenced by the imaging
screening modality. For most of our patients (66%), disease
progression was identiﬁed by PET scans. The widespread use of
PET for monitoring melanoma patients in Australia results in more
sensitive surveillance of progression compared to CT scans. In a
meta-analysis that pooled data from 74 studies containing 10,528
melanoma patients, PET was found to be superior to CT for the
surveillance of metastatic disease [35]. This PET improved
performance in depicting metastatic lesions over conventional
imaging modalities; however, CT has been commonly described in
the literature [36, 37].
Reconciling the ﬁndings of previous studies that used CT scan
as a mode of restaging [13, 14, 34], and with our observation
predominantly contrasted to PET scans, ctDNA detection rates at
progression is likely to have comparable if not superior sensitivity
when compared only to CT scans, given that there must be a
sizable volume of disease for a signiﬁcant increase to be detected.
Thus, the clinical utility of ctDNA for progressive disease
monitoring should be evaluated relative to the prevalent imaging
modality. Despite ctDNA not showing high detection rates when
compared with PET monitoring, its use may allow monitoring of
patients that live in rural areas, potentially aiding adjustment of
inequality of health access.
Previously, we have shown that patients with <10 MTB score,
which equates to a low disease burden, have ctDNA levels that fall
within the range of sampling error and therefore affect detection.
In addition, despite the high correlation found previously between
ctDNA levels and disease burden [8], we observed that ctDNA
levels do not correlate with MTB at the time of progression in
patients treated with targeted therapies. This also aligns with our
previous report that ctDNA is not predictive of outcome to secondline immunotherapy following targeted therapy failure [18].
It is possible that cellular mechanisms that mediate treatment
resistance may also interfere with cell apoptosis rates and ctDNA
shedding. The cellular mechanism through which ctDNA is shed is
poorly understood and its source has been extended to apoptotic
tumour cells [38], tumour-derived extracellular vesicles [39],
disseminated tumour cells and circulating tumour cells [40, 41].
However, no systematic study is yet to discover whether location
within an organ, vascularisation or mitotic rate affect the amount
of released ctDNA [42]. In addition, Smith et al. [43] have shown
that the number of macrophages and tumour necrosis factor-α

expression within the tumour is increased in patients treated with
BRAF and MEK inhibitors. The increased presence of macrophages
in relapsed tumours resistant to MAPK inhibitors might play an
important role in clearing apoptotic cells and maintaining low
ctDNA levels in the blood. Improved methods for the detection of
ctDNA need to be accompanied by an improved understanding of
the relationship between ctDNA release and the pathological state
of the tumour.
There are a few limitations in our retrospective study. The
timing of the blood collections relative to imaging scans varied
between patients. Given the short half-life of ctDNA, blood drawn
should ideally be conducted immediately prior to imaging to
ensure that the ctDNA detected is a true representation of the
lesions identiﬁed by the imaging technique. Moreover, preanalytical factors such as plasma separation time, centrifugation
speed or plasma extraction volume may also have affected our
results [44].
The targeted principle of the ddPCR assay may also be a limiting
factor in the detection rate of ctDNA at progression. Studies
exploring the use of untargeted methods that simultaneously
interrogate multiple cancer-speciﬁc variants based on the use of
NGS techniques have also been shown to improve both sensitivity
and speciﬁcity of ctDNA detection [45, 46]. As sequencing costs
are reduced, NGS-based untargeted strategies may become
clinically feasible.
In summary, our real-world cohort study highlights the urgent
need to improve the methods used to detect ctDNA at disease
progression and investigate the biological nature of ctDNA
shedding to increase the clinical application of this non-invasive
liquid biopsy. Future clinical trials with simultaneous imaging
evaluations and ctDNA plasma sampling are needed to accurately
deﬁne the clinical utility of ctDNA at detecting disease
progression.
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